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Abstracts / Osteoarthritis and Cartilage 21 (2013) S63–S312S242(non-transduced cells). A set of 53 downregulated genes pertaining to
the, canonical, planar, Cell Growth & Proﬁleration and Cell Migration,
were identiﬁed. One of them, DAAM1, have been already described as
direct targets of mir-335.
Conclusions: Our results indicate a lower expression of mir335 in OA-
MSCs patients and suggest that the downregulation in Wnt related
genes during the initial stages of differentiation that could be partly
restored after mir335 overexpression. Therefore, we hypothesize that
a diminished expression of mir335 could contribute to the altered
function of MSCs in OA.
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Purpose: Several studies reported that an increase of subchondral bone
area (tAB) is associatedwith features of radiographic knee osteoarthritis
(rOA), such as osteophytes, joint space narrowing or subchondral
defects. One cross-sectional study reported that tABs were larger in
knees with higher KL grades, based on site readings from the OA
initiative (OAI). Here we test the hypotheses that knees with rOA show
greater rates of longitudinal tAB change than knees with risk factors but
not deﬁnite radiographic OA (pre-rOA) or healthy knees without.
Methods: Coronal FLASHwe MR images of 899 right knees from OAI
participants (539 women, 360 men; age 61.69.5; BMI 28.94.8) were
acquired at baseline and 12 month follow-up (public use datasets 0.E.1
and 1.E.1). Based on central radiographic readings (Boston University),
101 knees were classiﬁed asymptomatic healthy controls (bilateral KLG
0, no OA risk factors), 254were pre-rOA (KLG 0&1, with risk factors), and
544 had deﬁnite rOA (KLG 2-4). The tAB of the medial and lateral tibia
(MT/LT) and weight-bearing (central) femoral condyles (cMF/cLF) were
segmented by experienced readers, by matching numbers of slices
processed per plate in scan pairs, but with blinding to acquisition order.
The size of the tAB was calculated in 3D. Because an increase in tAB was
expected, 1-sided non-paired t-tests were used to compare groups, and
signiﬁcance of change was assessed with 1-sided paired t-tests.
Results: tAB changes were less than 1% in all strata (Table 1) and were
not signiﬁcantly different from zero in healthy reference knees (SRM
range -0.10 to +0.11). Pre-rOA knees had a signiﬁcant (p<0.05) tAB
increase in cMF (SRM +0.10) but not in other plates (SRM 0.05). rOA
knees showed signiﬁcant tAB increases in MT (SRM +0.14), cMF (SRM
+0.21) and cLF (SRM +0.15), but not in LT (SRM +0.03). The changes were
signiﬁcantly greater than in rOA than in pre-rOA knees for MT and cLF
(p< 0.05), and greater than in healthy controls for MT (p<0.05). In MT,
the percent increase in tAB was greater in knees with higher KL grades.
Conclusions: Knees with deﬁnite rOA show small but signiﬁcant
longitudinal increases in tAB, predominantly in the medial compart-
ment. In the medial tibia, the rate of tAB changewas greater in rOA than
in pre-rOA or healthy knees. The observed relationship between tAB
change and rOAI status in the medial tibia may be due to rOA
predominantly affecting the medial compartment (in general and in the
OAI) and because femorotibial loading is known to be greater medially
than laterally. The current results suggest that longitudinal change in
tABs is a feature of structural progression associated with rOA status.Table 1
Change in the subchondral bone area (tAB [Mean%SEM]) over 12 months in OAI
knees
Group Size MT LT cMF cLF
Healthy n¼101 -0.11.2% -0.11.2% 0.21.1% 0.00.9%
Pre-rOA n¼254 0.00.8% 0.10.7% 0.20.6% 0.00.5%
KLG2 n¼316 0.10.7% 0.10.7% 0.30.5% 0.20.5%
KLG3 n¼167 0.21.1% 0.11.0% 0.50.9% 0.20.8%
KLG4 n¼61 0.32.1% -0.11.9% 0.31.5% 0.31.1%457
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Purpose: Subchondral bone changes are an important feature in oste-
oarthritis (OA). Initial loss of bone volume (BV) followed by sclerosis and
thickening of the subchondral bone plate occur during OA develop-
ment. STR/Ort mice have been suggested to develop OA spontaneously
due to reduced endogenous PPARa signalling, possibly by increasing
inﬂammatory processes in the joint and an altering osteoblast pheno-
type [Watters 2007, Arthritis Rheum]. To conﬁrm the role of PPARa in
the development of OA, we have treated STR/Ort mice with fenoﬁbrate,
a PPARa agonist, and evaluated inﬂammation, subchondral changes and
OA cartilage damage in this spontaneous OA model.
Methods: 8-weeks-old male STR/Ort mice (n¼36) were divided into 3
experimental groups (n¼12 per group). One group received reference
diet (Control) whereas the other 2 groups received reference diet mixed
with two different dosages of fenoﬁbrate (100mg/kg bodyweight (BW)/
day or 200 mg/kg BW/day). Mice were euthanized after 16 weeks of
treatment at the age of 6 months. mCT was used to quantify subchondral
bone volume (Sb.BV) in a pre-deﬁned region of interest and sub-
chondral plate thickness (Sb.Th), in addition to metaphyseal bone
volume fraction (BV/TV), trabecular thickness (Tb.Th), trabecular
number (Tb.N) and trabecular separation (Tb.Sp). Level of inﬂammation
was determined by measuring serum amyloid A (SAA). Knee cartilage
damage was evaluated by histology using the OARSI scoring method.
Results: Mice treated with 200 mg/kg BW/day fenoﬁbrate had a signiﬁ-
cantly lower amount of subchondral bone, with lower Sb.BV and Sb.Th, as
well as a lower amount of metaphyseal bone, with lower BV/TV and Tb.N
and elevated Tb.Sp. No signiﬁcant difference in cartilage damage was
found between the groups. Fenoﬁbrate treated mice had signiﬁcantly
lower levels of SAA compared to Control. Although no difference was
found in SAA levels between mice with and without cartilage damage,
reduced SAA was associated with less Sb.BV, BV/TV and Tb.Th.
Conclusions: Systemic inﬂammation and subchondral bone volume
and thickness in the STR/Ort mouse can be reduced by fenoﬁbrate
treatment. However, cartilage damagewas not inﬂuenced. This suggests
that PPARa signalling may inﬂuence subchondral bone morphology, but
is not correlated with cartilage damage in the STR/Ort mouse.
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Figure. Effect of treatment on (A) subchondral bone volume and (B) plate thickness,
(C) cartilage damage and (D) serum amyloid A levels. Indicated dosage is mg/kg
bodyweight/day.
